Recent News

• 05.08.2026 - InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
• 05.06.2026 - InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
• 03.31.2026 - InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium

Recent Filings

• 05.06.2026 - EX-99.1 EX-99.1
• 05.06.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.06.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 05.06.2026 - EX-99.1 EX-99.1
• 05.06.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.04.2026 - EX-99.1 EX-99.1
• 05.04.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.28.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.28.2026 - EX-99.1 EX-99.1
• 04.23.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]